Century Therapeutics, Inc. (IPSC) intrinsic value & 10-year financials
Century Therapeutics, Inc. (IPSC) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 7 fiscal years revenue grew 175.9% a year to $109.2M, with an average return on invested capital of -42.0%.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $1.37
- Market cap
- $118.6M
- Revenue (FY2025)
- $109.2M
- Revenue growth (7-yr CAGR)
- 175.9%
- ROIC (10-yr avg)
- -42.0%
- Free cash flow (FY2025)
- -$104.7M
IPSC 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $109.2M | -$9.6M | -$0.14 | -$104.7M | -15.8% | -11.9% |
| FY2024 | $6.6M | -$126.6M | -$1.61 | -$110.3M | -2096.5% | -82.2% |
| FY2023 | $2.2M | -$136.7M | -$2.27 | -$102.1M | -6556.9% | -71.0% |
| FY2022 | $5.2M | -$130.9M | -$2.27 | -$16.6M | -2574.2% | -46.3% |
| FY2021 | — | -$95.8M | -$2.96 | -$134.0M | — | -84.1% |
| FY2020 | — | -$53.6M | -$7.16 | -$51.1M | — | 43.2% |
| FY2019 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Century Therapeutics, Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Century Therapeutics, Inc. has historically struggled to out-earn its cost of capital, averaging just -42.0% ROIC.
Century Therapeutics, Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, Century Therapeutics, Inc. is modeled at 15.0% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $-4.65 per share.